See more : Jia Group Holdings Limited (8519.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Amryt Pharma plc (AMYT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Amryt Pharma plc, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Phoenix Copper Limited (PXC.L) Income Statement Analysis – Financial Results
- TAG Oil Ltd. (TAO.V) Income Statement Analysis – Financial Results
- WAM Leaders Limited (WLE.AX) Income Statement Analysis – Financial Results
- Hawaiian Electric Company, Inc. PFD SER D 5% (HAWEM) Income Statement Analysis – Financial Results
- Zedcor Inc. (ZDC.V) Income Statement Analysis – Financial Results
Amryt Pharma plc (AMYT)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.amrytpharma.com
About Amryt Pharma plc
Amryt Pharma plc, a commercial-stage biopharmaceutical company, focuses on acquiring, developing, and commercializing various treatments to help improve the lives of patients with rare and orphan diseases. The company provides metreleptin, an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy; oral octreotide, a long-term maintenance therapy in acromegaly patients; and lomitapide, an adjunct to a low-fat diet and other lipid-lowering medicinal products for adults with the Homozygous familial Hypercholesteraemia. Its development candidates include Oleogel-S10 for the cutaneous manifestations of Junctional and Dystrophic Epidermolysis Bullosa (EB), a rare and distressing genetic skin disorder affecting young children and adults; and AP103, a pre-clinical gene therapy for patients with dystrophic EB. The company sells its products in the Americas, Europe, and the Middle East. Amryt Pharma plc was founded in 2015 and is headquartered in Dublin, Ireland.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 222.54M | 182.61M | 58.12M | 16.53M | 15.33M | 1.42M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 106.12M | 119.03M | 42.00M | 6.06M | 6.45M | 616.30K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 116.42M | 63.58M | 16.12M | 10.47M | 8.88M | 804.55K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 52.32% | 34.82% | 27.74% | 63.35% | 57.95% | 56.62% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 37.73M | 27.62M | 15.83M | 10.35M | 12.67M | 2.47M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 8.34M | 4.73M | 841.00K | 17.57M | 13.25M | 4.25M | 3.33M | 2.93M | 1.87M | 275.37K | 281.22K | 1.72M | 1.74M | 3.05M | 2.33M |
| Selling & Marketing | 92.00M | 76.67M | 35.50M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 100.34M | 81.40M | 36.34M | 17.57M | 13.25M | 4.25M | 3.33M | 2.93M | 1.87M | 275.37K | 281.22K | 1.72M | 1.74M | 3.05M | 2.33M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -80.83K | -47.51K | 5.03K | 11.50K |
| Operating Expenses | 138.07M | 109.02M | 52.17M | 27.92M | 25.93M | 6.95M | 3.34M | 2.93M | 1.86M | 275.37K | 281.22K | 281.82K | 1.74M | 3.05M | 2.33M |
| Cost & Expenses | 244.18M | 228.05M | 94.17M | 33.98M | 32.37M | 7.57M | 3.34M | 2.93M | 1.86M | 275.37K | 281.22K | 281.82K | 1.74M | 3.05M | 2.33M |
| Interest Income | 5.00K | 87.00K | 92.00K | 5.72K | 6.00K | 1.05K | 185.00K | 201.00K | 319.07K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 27.91M | 19.57M | 8.48M | 1.78M | 989.75K | 127.26K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 50.74M | 44.47M | 12.63M | 354.61K | 310.72K | 204.03K | 6.00K | 6.00K | 4.56K | 0.00 | 99.63K | 147.69K | 144.69K | 224.23K | 161.09K |
| EBITDA | 29.10M | -977.00K | -23.42M | -17.09M | -16.73M | -5.94M | 33.26M | -3.10M | -1.27M | -275.37K | -281.22K | -281.82K | -1.60M | -2.83M | -2.17M |
| EBITDA Ratio | 13.08% | -0.54% | -40.29% | -103.36% | -109.16% | -418.28% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -21.64M | -45.44M | -36.04M | -17.44M | -17.04M | -8.08M | -39.93M | -2.93M | -3.51M | -275.37K | -281.22K | -281.82K | -459.87K | -3.28M | -2.43M |
| Operating Income Ratio | -9.72% | -24.89% | -62.01% | -105.51% | -111.18% | -568.69% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -8.17M | -60.42M | -30.72M | -12.00M | -14.31M | -127.26K | 189.00K | -36.81M | 376.00K | -1.84M | -5.85K | 0.00 | -63.03K | 7.94K | 14.28K |
| Income Before Tax | -29.81M | -105.86M | -66.76M | -29.45M | -31.36M | -8.21M | -39.74M | -2.56M | -2.12M | -275.37K | -281.22K | -281.82K | -522.90K | -3.27M | -2.41M |
| Income Before Tax Ratio | -13.40% | -57.97% | -114.86% | -178.09% | -204.54% | -577.65% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -11.64M | -1.33M | -1.23M | 41.18K | 14.31M | 1.93M | 73.18M | -175.00K | 2.23M | 550.74K | 2.68M | 1.51K | -25.79K | 226.22K | 101.27K |
| Net Income | -18.17M | -104.53M | -65.54M | -29.49M | -45.67M | -8.21M | -39.74M | -2.56M | -2.12M | -826.12K | -3.06M | -123.58K | -497.11K | -3.27M | -2.41M |
| Net Income Ratio | -8.17% | -57.24% | -112.75% | -178.34% | -297.89% | -577.65% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.39 | -2.92 | -4.32 | -3.22 | -6.14 | -1.51 | -3.45 | -0.26 | -0.33 | -0.08 | -0.30 | -0.01 | -0.05 | -0.42 | 0.00 |
| EPS Diluted | -0.37 | -2.92 | -4.32 | -3.22 | -6.14 | -1.51 | -3.45 | -0.26 | -0.33 | -0.08 | -0.30 | -0.01 | -0.05 | -0.42 | 0.00 |
| Weighted Avg Shares Out | 47.17M | 35.76M | 15.17M | 9.16M | 7.44M | 5.44M | 11.51M | 9.81M | 6.47M | 10.12M | 10.12M | 10.12M | 9.59M | 7.87M | 0.00 |
| Weighted Avg Shares Out (Dil) | 49.40M | 35.76M | 15.17M | 9.16M | 7.44M | 5.44M | 11.51M | 9.81M | 6.47M | 10.12M | 10.12M | 10.12M | 9.59M | 7.87M | 0.00 |
Amryt (AMYT) NDA for Skin Disorder Drug Gets Priority Review
Amryt Pharma's Oleogel-S10 Application Gets FDA Priority Review Tag for Skin Blistering Disorder
Amryt Pharma new drug application for rare skin condition fast-tracked by US Food & Drug Administration
Amryt Pharma new drug application for rare skin condition fast-tracked by the US Food & Drug Administration
FDA Grants Priority Review for New Drug Application for Oleogel-S10 for the Treatment of Epidermolysis Bullosa
Amryt Pharma gets FDA approval for new drug application
Amryt Pharma plc (AMYT) Amryt Pharma Acquisition of Chiasma Inc. and Q1 2021 Earnings Conference (Transcript)
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Chiasma, Inc.
Amryt Reports Record Q1 2021 Financial and Operating Results
Amryt Announces the Appointment of Sheila Frame as President Americas
Source: https://incomestatements.info
Category: Stock Reports